Targovax AS Raises $3.6 Million in Private and Public Support for TG01 Pancreatic Cancer Vaccine Development
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
OSLO, Norway--(BUSINESS WIRE)--Cancer vaccine specialist Targovax today announced that it has raised a total of $3.6 million to accelerate development of its RAS mutation-targeted therapeutic cancer vaccine pipeline, specifically lead candidate TG01 for pancreatic cancer. The funds comprise $2.3 million in public support from the Norwegian Research Council’s BIA programme and $1.3 million from existing and new investors, including the Radium Hospital Research Foundation, Algot Invest and Trygve Schiørbeck.
Help employers find you! Check out all the jobs and post your resume.
OSLO, Norway--(BUSINESS WIRE)--Cancer vaccine specialist Targovax today announced that it has raised a total of $3.6 million to accelerate development of its RAS mutation-targeted therapeutic cancer vaccine pipeline, specifically lead candidate TG01 for pancreatic cancer. The funds comprise $2.3 million in public support from the Norwegian Research Council’s BIA programme and $1.3 million from existing and new investors, including the Radium Hospital Research Foundation, Algot Invest and Trygve Schiørbeck.
Help employers find you! Check out all the jobs and post your resume.